Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06556563
Title EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma (EF-41)
Acronym EF-41
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors NovoCure GmbH
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
UF Health Neuromedicine RECRUITING Gainesville Florida 32608 United States Details
Swedish Medical Center RECRUITING Seattle Washington 98122 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field